# The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-benefits-and-risks-of-switching-from-fingolimod-to-siponimod-for-the/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Martin Vališ,Anat Achiron,Hans Hartung,Jan Mareš,Veronika Tichá,Pavel Štourač,Simona Halúsková,Francesco Angelucci,Zbyšek Pavelek |
| Citations | 18 |
| DOI | 10.1007/s40268-023-00434-6 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://link.springer.com/content/pdf/10.1007/s40268-023-00434-6.pdf |
| OpenAlex ID | https://openalex.org/W4386212010 |
| PMID | 37640862 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Zbyšek Pavelek](https://scholariq.org/researchers/zbysek-pavelek/)

## Paper primary topic

- [Sphingolipid Metabolism and Signaling](https://scholariq.org/topics/sphingolipid-metabolism-and-signaling/)

## Paper topics

- [Sphingolipid Metabolism and Signaling](https://scholariq.org/topics/sphingolipid-metabolism-and-signaling/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [NF-κB Signaling Pathways](https://scholariq.org/topics/nf-b-signaling-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.